CN102638987A - 使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法 - Google Patents

使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法 Download PDF

Info

Publication number
CN102638987A
CN102638987A CN2010800550891A CN201080055089A CN102638987A CN 102638987 A CN102638987 A CN 102638987A CN 2010800550891 A CN2010800550891 A CN 2010800550891A CN 201080055089 A CN201080055089 A CN 201080055089A CN 102638987 A CN102638987 A CN 102638987A
Authority
CN
China
Prior art keywords
mmol
methyl
tert
antagonist
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800550891A
Other languages
English (en)
Chinese (zh)
Inventor
H.纳加布库罗
S.D.埃蒙森
M.S.辛哈罗伊
W.S.丹尼
T.L.弗伦克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN102638987A publication Critical patent/CN102638987A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN2010800550891A 2009-10-07 2010-09-27 使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法 Pending CN102638987A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24938609P 2009-10-07 2009-10-07
US61/249386 2009-10-07
PCT/US2010/050328 WO2011043942A1 (en) 2009-10-07 2010-09-27 Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent

Publications (1)

Publication Number Publication Date
CN102638987A true CN102638987A (zh) 2012-08-15

Family

ID=43857059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800550891A Pending CN102638987A (zh) 2009-10-07 2010-09-27 使用β3肾上腺素能受体激动剂和抗毒蕈碱药剂的组合疗法

Country Status (15)

Country Link
US (1) US20120202819A1 (enExample)
EP (1) EP2485595A4 (enExample)
JP (1) JP5738871B2 (enExample)
KR (1) KR20120093859A (enExample)
CN (1) CN102638987A (enExample)
AU (1) AU2010303811B2 (enExample)
BR (1) BR112012007829A2 (enExample)
CA (1) CA2774992A1 (enExample)
IL (1) IL218756A0 (enExample)
IN (1) IN2012DN02782A (enExample)
MX (1) MX2012004134A (enExample)
NZ (1) NZ599233A (enExample)
RU (1) RU2012118668A (enExample)
WO (1) WO2011043942A1 (enExample)
ZA (1) ZA201202520B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111556753A (zh) * 2017-12-21 2020-08-18 杏林制药株式会社 用于夜间尿频的治疗剂

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642661B2 (en) * 2010-08-03 2014-02-04 Altherx, Inc. Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EP3167885A1 (en) * 2011-05-10 2017-05-17 TheraVida, Inc. Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
US9809536B2 (en) 2011-10-27 2017-11-07 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
JP6063948B2 (ja) * 2011-10-27 2017-01-18 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ベータ３アゴニストおよび中間体を製造するプロセス
SG11201404776PA (en) * 2012-02-09 2014-09-26 Altherx Inc Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
SMT201900508T1 (it) * 2013-03-15 2019-11-13 Merck Sharp & Dohme Processo per preparare beta 3 agonisti e intermedi
ES2910361T3 (es) * 2013-07-23 2022-05-12 Serenity Pharmaceuticals Llc Composiciones que comprenden desmopresina en combinación con un agonista del receptor adrenérgico beta-3
CN106999538A (zh) 2014-11-20 2017-08-01 阿勒根公司 包含去氨加压素与α‑肾上腺素能受体拮抗剂组合的方法和组合物
KR20170086659A (ko) 2014-12-03 2017-07-26 벨리셉트 테라퓨틱스, 인크. 하부 요로 증상을 위한 변형 방출형 솔라베그론을 이용한 조성물 및 방법
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
US10065922B2 (en) 2015-10-23 2018-09-04 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
WO2018039159A1 (en) * 2016-08-22 2018-03-01 Chase Pharmaceuticals Corporation Muscarinic m2-antagonist combination
KR20250099259A (ko) 2017-06-06 2025-07-01 유로반트 사이언시즈 게엠베하 과민성 방광의 치료를 위한 비베그론의 용도
CN110869053A (zh) * 2017-06-06 2020-03-06 乌洛万特科学有限公司 给药维贝隆以治疗膀胱过度活动症
WO2020115705A1 (en) 2018-12-05 2020-06-11 Urovant Sciences Gmbh Vibegron for the treatment of overactive bladder symptoms
CN115850286B (zh) * 2022-12-05 2023-08-22 奥锐特药业(天津)有限公司 一种维贝格龙中间体及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291491B1 (en) * 1999-10-12 2001-09-18 Merck & Co., Inc. Amide derivatives as β 3 agonists
US6413984B1 (en) * 1999-02-02 2002-07-02 Sanofi-Synthelabo 8-(heterocyclylmethyl)quinoline derivatives for treating urinary incontinence
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2008121268A1 (en) * 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
WO2009124166A1 (en) * 2008-04-04 2009-10-08 Merck & Co., Inc. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024483A1 (fr) * 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413984B1 (en) * 1999-02-02 2002-07-02 Sanofi-Synthelabo 8-(heterocyclylmethyl)quinoline derivatives for treating urinary incontinence
US6291491B1 (en) * 1999-10-12 2001-09-18 Merck & Co., Inc. Amide derivatives as β 3 agonists
US20040248979A1 (en) * 2003-06-03 2004-12-09 Dynogen Pharmaceuticals, Inc. Method of treating lower urinary tract disorders
WO2008121268A1 (en) * 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
WO2009124166A1 (en) * 2008-04-04 2009-10-08 Merck & Co., Inc. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKIYOSHI OHTAKE ET AL: "Pharmacological Characterization of New Antimuscarinic Agent, Solifenacin Succinate, in Comparison with Other Antimuscarinic Agents", 《BIOL. PHARM. BULL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111556753A (zh) * 2017-12-21 2020-08-18 杏林制药株式会社 用于夜间尿频的治疗剂

Also Published As

Publication number Publication date
WO2011043942A1 (en) 2011-04-14
ZA201202520B (en) 2012-12-27
US20120202819A1 (en) 2012-08-09
RU2012118668A (ru) 2013-11-20
JP2013507363A (ja) 2013-03-04
AU2010303811A1 (en) 2012-04-19
MX2012004134A (es) 2012-05-08
AU2010303811B2 (en) 2013-01-24
KR20120093859A (ko) 2012-08-23
NZ599233A (en) 2013-04-26
IL218756A0 (en) 2012-06-28
BR112012007829A2 (pt) 2015-09-22
JP5738871B2 (ja) 2015-06-24
EP2485595A1 (en) 2012-08-15
EP2485595A4 (en) 2014-03-12
IN2012DN02782A (enExample) 2015-09-18
CA2774992A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
JP5738871B2 (ja) β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法
US8247415B2 (en) Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
US8748433B2 (en) β3 adrenergic receptor agonists
EP2427194B1 (en) Pyrrolidine-derived beta 3 adrenergic receptor agonists
CN103140134B (zh) 新吡咯烷衍生的β3肾上腺素能受体激动剂
HK1147099B (en) Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SCHERING CORP (US)

Free format text: FORMER OWNER: MSD CORP.

Effective date: 20121119

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: New jersey, USA

Applicant after: MERCK SHARP & DOHME Corp.

Address before: New jersey, USA

Applicant before: SCHERING Corp.

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

TA01 Transfer of patent application right

Effective date of registration: 20121119

Address after: New jersey, USA

Applicant after: SCHERING Corp.

Address before: New jersey, USA

Applicant before: MERCK SHARP & DOHME Corp.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120815